{"id":"NCT02544451","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor","officialTitle":"A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-08","primaryCompletion":"2018-08","completion":"2020-04","firstPosted":"2015-09-09","resultsPosted":"2019-10-29","lastUpdate":"2021-05-24"},"enrollment":246,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"LUM/IVA","otherNames":["VX-809/VX-770","lumacaftor/ivacaftor"]},{"type":"DRUG","name":"LUM/IVA","otherNames":["VX-809/VX-770","lumacaftor/ivacaftor"]}],"arms":[{"label":"Treatment Period 1: LUM/IVA to LUM/IVA","type":"EXPERIMENTAL"},{"label":"Treatment Period 1: Placebo (PBO) to LUM/IVA","type":"EXPERIMENTAL"},{"label":"Treatment Period 1: Observational Cohort","type":"NO_INTERVENTION"},{"label":"Treatment Period 2: LUM/IVA","type":"EXPERIMENTAL"}],"summary":"Study 110 is a Phase 3, multicenter study in subjects aged 6 years and older with cystic fibrosis (CF) who are homozygous for the F508del-CF transmembrane conductance regulator (CFTR) mutation and who participated in Study 109 (NCT02514473) or Study 011B (NCT01897233). Study 110 is designed to evaluate the safety and efficacy of long term treatment of lumacaftor in combination with ivacaftor.","primaryOutcome":{"measure":"Treatment Period 1 (Treatment Cohorts): Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)","timeFrame":"Day 1 up to Week 100","effectByArm":[{"arm":"LUM/IVA to LUM/IVA","deltaMin":142,"sd":null},{"arm":"PBO to LUM/IVA","deltaMin":94,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":60,"countries":["United States","Australia","Belgium","Canada","Denmark","France","Germany","Sweden","United Kingdom"]},"refs":{"pmids":["33516285"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":43,"n":143},"commonTop":["Cough","Infective pulmonary exacerbation of cystic fibrosis","Pyrexia","Headache","Nasal congestion"]}}